ChromoCure, Inc. (KKUR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ChromoCure, Inc. (KKUR) trades at $0.000001 with AI Score 46/100 (Grade C). ChromoCure, Inc. is a healthcare company specializing in cancer detection systems. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for KKUR: KKUR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KKUR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
KKUR: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
ChromoCure, Inc. (KKUR) Healthcare & Pipeline Overview
ChromoCure, Inc. focuses on developing and providing cancer detection systems, primarily the Chromosomal Scanner Series 200. This system aims to detect genomic characteristics specific to cancer cells, positioning the company within the niche market of specialized cancer diagnostics and research tools, though its market capitalization is currently $0.
What Is the Investment Thesis for KKUR?
ChromoCure, Inc. presents a high-risk, high-reward investment profile. The company's Chromosomal Scanner Series 200 technology, if validated and successfully commercialized, could represent a significant advancement in cancer detection. However, the company's $0 market capitalization and OTC listing indicate substantial challenges. The success of ChromoCure hinges on its ability to secure funding, complete clinical trials, and gain regulatory approvals. Key value drivers include the successful demonstration of the Chromosomal Scanner's efficacy and the establishment of strategic partnerships. Growth catalysts include potential breakthroughs in cancer therapy research and the expansion of the Chromosomal Scanner's applications. The company's beta of -10.90 suggests an inverse correlation with the market, but this may be due to the stock's illiquidity and speculative nature.
Based on FMP financials and quantitative analysis
KKUR Key Highlights
ChromoCure, Inc. operates in the specialized medical sector, focusing on cancer detection systems.
- The company's primary product is the Chromosomal Scanner Series 200, designed to identify genomic characteristics unique to cancer cells.
- ChromoCure's market capitalization is $0.00B, indicating a micro-cap or nano-cap status.
- The company's beta is -10.90, suggesting an inverse correlation with the market, but this may be due to the stock's illiquidity.
- ChromoCure has a small team of 4 employees, reflecting a lean operational structure.
Who Are KKUR's Competitors?
KKUR is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACIXF Acarix AB (publ) | $0.03 | +0.00% | $31.5M | 52 |
| TRXDW TransEnterix, Inc. | $0.15 | -11.76% | $40.1M | 53 |
| EBRCZ EBR Systems, Inc. | $0.21 | -11.02% | $134M | 45 |
| SI SHOULDER INNOVATIONS, INC. | $23.26 | +10.08% | $482M | 30 |
| AVNBF Avon Technologies Plc | $22.49 | +0.00% | $662M | 38 |
| EBOSY EBOS Group Limited | $26.00 | +0.00% | $1.33B | 42 |
| BMXXY bioMérieux S.A. | $8.56 | +7.81% | $10.1B | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KKUR's Key Strengths?
Proprietary Chromosomal Scanner Series 200 technology.
- Focus on non-toxic and non-invasive cancer therapy research.
- Potential for early and accurate cancer detection.
- Experienced team in cancer genomics (assumed).
What Are KKUR's Weaknesses?
Limited financial resources ($0 market cap).
- Small team size (4 employees).
- OTC listing indicates higher risk and lower liquidity.
- Dependence on a single product (Chromosomal Scanner Series 200).
What Could Drive KKUR Stock Higher?
Publication of clinical trial results for the Chromosomal Scanner Series 200 (timeline unknown).
- Potential FDA approval for the Chromosomal Scanner Series 200 (timeline unknown).
- Strategic partnerships with research institutions to validate the technology.
- Development of non-toxic cancer therapies based on cancer genomics.
- Pursuit of funding opportunities through grants and venture capital.
What Are the Key Risks for KKUR?
Limited financial resources and dependence on external funding.
- Competition from established players in the cancer diagnostics market.
- Regulatory hurdles and approval processes.
- Technological obsolescence.
- Low liquidity and price volatility due to OTC listing.
What Are the Growth Opportunities for KKUR?
- Expansion of Chromosomal Scanner Applications: ChromoCure can explore expanding the applications of its Chromosomal Scanner Series 200 beyond research settings. This includes targeting clinical applications for early cancer detection and personalized medicine. The market for personalized medicine is projected to reach $2.4 billion by 2027, presenting a substantial opportunity for ChromoCure to integrate its technology into clinical workflows. This expansion requires further validation of the scanner's efficacy and regulatory approvals, with a potential timeline of 3-5 years.
- Strategic Partnerships with Research Institutions: Collaborating with leading research institutions and cancer centers can accelerate the validation and adoption of ChromoCure's technology. These partnerships can provide access to clinical data, expertise, and funding opportunities. The global research and development spending in the healthcare sector is estimated to be $240 billion in 2026, offering potential avenues for collaborative research projects. Establishing these partnerships within the next 1-2 years can significantly enhance ChromoCure's credibility and market reach.
- Development of Non-Toxic Cancer Therapies: Leveraging its understanding of cancer genomics, ChromoCure can focus on developing non-toxic and non-invasive cancer therapies. This aligns with the growing demand for gentler and more targeted cancer treatments. The market for targeted cancer therapies is projected to reach $115 billion by 2028, indicating a significant opportunity for ChromoCure to develop innovative therapeutic solutions. This development process typically involves preclinical research, clinical trials, and regulatory approvals, with a timeline of 5-7 years.
- Geographic Expansion into Emerging Markets: Expanding into emerging markets with high cancer incidence rates can drive revenue growth for ChromoCure. These markets often have unmet needs for advanced cancer diagnostics and therapies. The Asia-Pacific region is expected to be the fastest-growing market for cancer diagnostics, with a projected growth rate of 12% annually. Entering these markets requires adapting the company's business model and regulatory strategies, with a potential timeline of 2-3 years.
- Securing Funding and Grants: Obtaining funding through grants, venture capital, or strategic investments is crucial for supporting ChromoCure's research and development efforts. Government grants and private funding initiatives often target innovative cancer detection and treatment technologies. The National Cancer Institute (NCI) provides billions of dollars in funding for cancer research annually, representing a potential source of financial support for ChromoCure. Actively pursuing these funding opportunities within the next year can provide the necessary resources for advancing the company's pipeline.
What Are KKUR's Competitive Advantages?
- Proprietary technology in cancer detection.
- Potential intellectual property protection for the Chromosomal Scanner Series 200.
- Specialized expertise in cancer genomics.
- Potential for network effects through collaborations with research institutions.
What Does KKUR Do?
ChromoCure, Inc., originally incorporated as Cyberhand Technologies International, Inc. in 2001, rebranded in June 2009 to reflect its focus on cancer detection technologies. Based in Reno, Nevada, the company develops and provides proprietary cancer detection systems, most notably the Chromosomal Scanner Series 200. This system is designed to measure genomic characteristics found in all cancers but not in normal cells. ChromoCure aims to apply its scientific and technological expertise to develop non-toxic and non-invasive approaches to cancer therapy and cure research. The company's core business revolves around the development, manufacturing, and potential commercialization of its Chromosomal Scanner Series 200. This technology is intended for use in research settings and potentially clinical applications, offering a tool for early and accurate cancer detection. The company's evolution reflects a strategic shift towards specializing in cancer diagnostics and therapeutics, leveraging its technology to address unmet needs in the healthcare sector. With a small team of 4 employees, ChromoCure operates with a lean structure, focusing its resources on research and development efforts.
What Products and Services Does KKUR Offer?
- Develops proprietary cancer detection systems.
- Offers the Chromosomal Scanner Series 200.
- The Chromosomal Scanner Series 200 measures genomic characteristics found in all cancers.
- Applies science and technology to non-toxic cancer therapy research.
- Focuses on non-invasive approaches to cancer therapy.
How Does KKUR Make Money?
- Develops and sells cancer detection systems.
- Generates revenue through the sale of the Chromosomal Scanner Series 200.
- Potentially generates revenue through licensing agreements or partnerships.
- May generate revenue from cancer therapy research and development.
What Industry Does KKUR Operate In?
ChromoCure, Inc. operates within the medical specialties sector, specifically targeting cancer diagnostics and research. The cancer diagnostics market is experiencing growth, driven by increasing cancer incidence, advancements in technology, and a growing demand for early and accurate detection methods. Competitors include companies developing advanced diagnostic tools and therapies, such as ACNV, AHGIF, BTAX, CEVE, and GSRX. ChromoCure's success depends on its ability to differentiate its technology and establish a competitive advantage in this landscape. The company's focus on non-toxic and non-invasive approaches to cancer therapy aligns with current trends in the healthcare industry.
Who Are KKUR's Key Customers?
- Research institutions.
- Cancer centers.
- Hospitals.
- Pharmaceutical companies (potentially).
Key Financial Metrics
Return on equity for ChromoCure, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. KKUR trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
KKUR Valuation & Market Position
Relative to its peer group, KKUR's quantitative score of 46/100 is roughly in line with the peer average of 44/100.
Company Profile
ChromoCure, Inc. operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Reno, US. KKUR has traded publicly since 2005.
KKUR Financials
Bull Case vs Bear Case
Bull Case
- Proprietary Chromosomal Scanner Series 200 technology.
- Focus on non-toxic and non-invasive cancer therapy research.
- Potential for early and accurate cancer detection.
- Experienced team in cancer genomics (assumed).
Bear Case
- Limited financial resources ($0 market cap).
- Small team size (4 employees).
- OTC listing indicates higher risk and lower liquidity.
- Dependence on a single product (Chromosomal Scanner Series 200).
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
KKUR Latest News
No recent news available for KKUR.
KKUR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KKUR.
Price Targets
Wall Street price target analysis for KKUR.
KKUR MoonshotScore
What does this score mean?
The MoonshotScore rates KKUR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
KKUR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ChromoCure, Inc. may not meet the minimum financial or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, minimal assets, and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud or manipulation. These companies are not required to adhere to the same rigorous standards as those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or scams.
- Limited regulatory oversight.
- Verify the company's financial statements (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review any available news articles or press releases about the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investing.
- Check for any regulatory actions or investigations against the company.
- Company has been in operation since 2001.
- Focus on cancer detection systems, a legitimate area of healthcare.
- Development of a specific product (Chromosomal Scanner Series 200).
- Company has a physical headquarters in Reno, Nevada.
- Name change to reflect focus on cancer diagnostics.
ChromoCure, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for KKUR?
KKUR holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. ChromoCure, Inc. is a healthcare company specializing in cancer detection systems. Their primary offering is the Chromosomal Scanner Series 200, designed to identify genomic characteristics unique …
What does ChromoCure, Inc. do?
ChromoCure, Inc. is a healthcare company focused on developing and providing proprietary cancer detection systems. Their core product is the Chromosomal Scanner Series 200, designed to identify genomic characteristics present in all cancer cells but absent in normal cells. The company aims to leverage this technology for early cancer detection and the development of non-toxic and non-invasive cancer therapies.
What are the potential revenue streams for ChromoCure, Inc. in the healthcare sector?
ChromoCure, Inc.'s potential revenue streams in healthcare primarily revolve around its Chromosomal Scanner Series 200. These include direct sales of the scanner to research institutions and cancer centers, licensing agreements for the technology, and potential future revenue from the development and commercialization of non-toxic cancer therapies. The company may also generate revenue through collaborative research projects and grants.
What are the main risks for KKUR?
ChromoCure, Inc. faces several significant risks. As an OTC-listed company with a $0 market capitalization, it has limited financial resources and is highly dependent on securing external funding. Competition from established players in the cancer diagnostics market poses a substantial threat.
What are the key factors to evaluate for KKUR?
ChromoCure, Inc. (KKUR) holds an AI score of 46/100 (low). presents a high-risk, high-reward investment profile. The company's Chromosomal Scanner Series 200 technology, if validated and successfully commercialized, could represent a significant advancement in cancer detection. Not financial advice.
How frequently does KKUR data refresh on this page?
KKUR's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven KKUR's recent stock price performance?
ChromoCure, Inc. (KKUR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Chromosomal Scanner Series 200 technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KKUR overvalued or undervalued right now?
ChromoCure, Inc. (KKUR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research KKUR before investing?
Before investing in ChromoCure, Inc. (KKUR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC status and $0 market capitalization.
- AI analysis is pending, which may provide further insights into the company's prospects.
- The company's future success is highly dependent on securing funding and achieving regulatory approvals.